A RANKL-inducible gene Znf216 in osteoclast differentiation

Journal of Receptors and Signal Transduction

Volumn 25, Issue 3, 2005, Pages 199-216

  Hishiya, Akinori ^a   Ikeda, Kyoji ^a   Watanabe, Ken ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

cDNA microarray; RANKL; ZNF216

Indexed keywords

COLONY STIMULATING FACTOR 1; COMPLEMENTARY DNA; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; ZINC FINGER PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STIMULATION; DNA MICROARRAY; GENE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC REGULATION; MACROPHAGE ACTIVATION; MINERALIZATION; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; ZNF216 GENE;

ANIMALS; BLOTTING, NORTHERN; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; DNA; DNA, COMPLEMENTARY; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-1; LIGANDS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MONOCYTES; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMIDS; PROTEINS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; ZINC FINGERS;

EID: 26444495582     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890500240781     Document Type: Article

References (45)

1. Ash P, Loutit JF, Townsend KM. Osteoclasts derived from haematopoietic stem cells. Nature 1980, 283, 669-670.
2. Suda T, Udagawa N, Takahashi N. Osteoclast generation. In: (Bilezikian JP, Raisz LG, Rodan CA, Eds. Principles of Bone Biology. San Diego: Academic Press, 1996, 87-102.
3. Roodman GD. Advances in bone biology: The osteoclast. Endocr Rev 1996, 17; 308-332.
4. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene Nature 1990, 345, 442-444.
5. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. J Bone Miner Res 1989, 4, 113-118.
6. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191, 275-286.
7. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93, 165-176
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95, 3597-3602.
9. Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, Morony S, Oliveirados-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397, 315-323
10. Li J, Sarosi I, Yan X-Q, Morony S, Capparelli C, Tan H-L, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan S-C, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97, 1566-1571.
11. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998, 188, 997-1001.
12. Lotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997, 3, 1285-1289.
13. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266, 443-448.
14. Wagner EF, Matsuo K. Signalling in osteoclasts and the role of Fos/AP1 proteins. Ann Rheum Dis 2003, 62, 83-85.
15. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64, 693-702.
16. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992, 90, 1622-1627.
17. Tanaka S, Takahashi N, Udagawa N, Sasaki T, Fukui Y, Kurokawa T, Suda T. Osteoclasts express high levels of p60c-src, preferentially on ruffled border membranes. FEBS Lett 1992, 313, 85-89.
18. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, Sakurai N. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 2002, 22, 992-1000.
19. Yousef, AA. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κ B J Clin Invest 2001, 107, 1375-1385.
20. Battaglino R, Kim D, Fu J, Vaage B, Fu XY, Stashenko P. c-myc is required for osteoclast differentiation. J Bone Miner Res 2002, 17, 763-773.
21. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279, 26475-26480.
22. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFNγ. Nature 2000, 408, 600-605.
23. Scott DA, Greinwald JH, Jr, Marietta JR, Drury S, Swiderski RE, Vinas A, DeAngelis MM, Carmi R, Ramesh A, Kraft ML, Elbedour K, Skworak AB, Friedman RA, Srikumari Srisailapathy CR, Verhoeven K, Van Gamp G, Lovett M, Deininger PL, Batzer MA, Morton CC, Keats BJ, Smith RJ, Sheffield VC. Identification and mutation analysis of a cochlear-expressed, zinc finger protein gene at the DFNB7/11 and dn hearing-loss loci on human chromosome 9q and mouse chromosome 19. Gene 1998, 215, 461-469.
24. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15, 2-12.
25. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem, 1982, 257, 7847-7851.
26. Hirano M, Hirai S, Mizuno K, Osada S, Hosaka M, Ohno S. A protein kinase C isoenzyme, nPKCε, is involved in the activation of NF-κB by 12-O-tetradecanoylphorbol-13-acetate (TPA) in rat 3Y1 fibroblasts. Biochem Biophys Res Commun 1995, 206, 429-436.
27. Chen Y, Wu Q, Song S-Y, Su W-J. Activation of JNK by TPA promotes apoptosis via PKC pathway in gastric cancer cells. World J. Gastroenterol 2002, 8, 1014-1018.
28. Linnen JM, Bailey CP, Weeks D. L. Two related localized mRNAs from Xenopus laevis encode ubiquitin-like fusion proteins. Gene 1993, 128, 181-188
29. Huang J, Teng L, Li L, Liu T, Li L, Chen D, Xu LG, Zhai Z, Shu HB. ZNF216 is an A20-like and IκB kinase γ-interacting inhibitor of NFκB activation. J Biol Chem 2004, 279, 16847-16853.
30. Whiteside ST, Israel A. IκB proteins: Structure, function and regulation. Semin Cancer Biol 1997, 8, 75-82.
31. Kaifu T, Nakahara J, Inui M, Mishima K, Momiyama T, Kaji M, Sugahara A, Koito H, Ujike-Asai A, Nakamura A, Kanazawa K, Tan-Takeuchi K, Iwasaki K, Yokoyama WM, Kudo A, Fujiwara M, Asou H, Takai T. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003, 111, 323-332.
32. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428, 758-763.
33. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, Majumdar S, Lanier LL, Lowell CA, Nakamura MC. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004, 101, 6158-6163.
34. Daeron M. Fc receptor biology. Annu Rev Immunol 1997, 15, 203-234.
35. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. J Immunol 1999, 162, 5-8.
36. Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A, Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med 2003, 198, 645-651.
37. Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 2003, 198, 669-675.
38. Takayanagi H, Kim S, Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 2002a, 4, S227-S232.
39. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002b, 416, 744-749.
40. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation Nat Genet 2000, 24, 184-187.
41. Palokangas H, Mulari M, Vaananen HK. Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts. J Cell Sci 1997, 110, 1767-1780.
42. Stenbeck G. Formation and function of the ruffled border in osteoclasts. Semin Cell Dev Biol 2002, 13, 285-292.
43. Gowen M, Mundy GR. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol 1986, 136, 2478-2482.
44. Takahashi N, Mundy GR, Roodman GD. Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. J Immunol 1986, 137, 3544-3549.
45. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. 2004, 430, 694-699.